Metergoline as a lactation inhibitor. 1982

A Caballero, and A Palomo, and C E Molina, and F J Albarrán, and A Caballero, and P Mena

For the prevention of lactation we administered metergoline, 12 to 16 mg per day for five to ten days, to six groups of 100 patients each with excellent or good results in 95% to 99% of the cases. In addition, metergoline was given to 100 patients in order to suppress previously established lactation, with excellent or good results in 100% of the cases. The decrease of prolactin during the first 21 days of metergoline administration was compared with that in a group given bromoergocriptine (5 mg per day) and with that in a breast-binding control group. Metergoline is effective and does not have secondary effects in the inhibition and suppression of lactation due to its antiserotonin and dopaminergic effects.

UI MeSH Term Description Entries
D007774 Lactation The processes of milk secretion by the maternal MAMMARY GLANDS after PARTURITION. The proliferation of the mammary glandular tissue, milk synthesis, and milk expulsion or let down are regulated by the interactions of several hormones including ESTRADIOL; PROGESTERONE; PROLACTIN; and OXYTOCIN. Lactation, Prolonged,Milk Secretion,Lactations, Prolonged,Milk Secretions,Prolonged Lactation,Prolonged Lactations
D008711 Metergoline A dopamine agonist and serotonin antagonist. It has been used similarly to BROMOCRIPTINE as a dopamine agonist and also for MIGRAINE DISORDERS therapy. Methergoline,Liserdol
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

A Caballero, and A Palomo, and C E Molina, and F J Albarrán, and A Caballero, and P Mena
February 1987, The Journal of reproductive medicine,
A Caballero, and A Palomo, and C E Molina, and F J Albarrán, and A Caballero, and P Mena
January 1978, Obstetrics and gynecology,
A Caballero, and A Palomo, and C E Molina, and F J Albarrán, and A Caballero, and P Mena
January 1983, Nihon Sanka Fujinka Gakkai zasshi,
A Caballero, and A Palomo, and C E Molina, and F J Albarrán, and A Caballero, and P Mena
March 1977, British medical journal,
A Caballero, and A Palomo, and C E Molina, and F J Albarrán, and A Caballero, and P Mena
January 1995, Zeitschrift fur Geburtshilfe und Neonatologie,
A Caballero, and A Palomo, and C E Molina, and F J Albarrán, and A Caballero, and P Mena
January 1974, Gynecologic investigation,
A Caballero, and A Palomo, and C E Molina, and F J Albarrán, and A Caballero, and P Mena
January 1983, Gynecologic and obstetric investigation,
A Caballero, and A Palomo, and C E Molina, and F J Albarrán, and A Caballero, and P Mena
December 1980, Haematologica,
A Caballero, and A Palomo, and C E Molina, and F J Albarrán, and A Caballero, and P Mena
January 1982, European journal of clinical pharmacology,
A Caballero, and A Palomo, and C E Molina, and F J Albarrán, and A Caballero, and P Mena
January 1987, Gynecologic and obstetric investigation,
Copied contents to your clipboard!